Abstract | BACKGROUND: OBJECTIVE: To evaluate the analgesic effect and the impact on quality of life after a single application of the capsaicin 8% cutaneous patch in patients with lumbosacral pain. STUDY DESIGN: Prospective open-label study of capsaicin 8% patch in patients with lumbosacral pain. SETTING: METHODS: All recruited patients were evaluated prior to capsaicin 8% patch administration and were followed-up at 2 weeks, at 8 weeks, and at 12 weeks post administration. Visual analog scale (VAS) was used to record pain intensity and EQ-5D was used to assess the quality of life of the participants. RESULTS: Ninety patients met our inclusion criteria (54.4% men, mean age 59.1 ± 9.2 years). At baseline the mean VAS score of the participants was 7.6 ± 0.7. A statistically significant reduction of the VAS score between baseline and week 2 (mean VAS score 5.6 ± 1.1, P < 0.001) was observed. The therapeutic effect further continued between week 2 and week 8 (mean VAS score 3.2 ± 1.2, P < 0.001) and between week 8 and at endpoint at week 12 (mean VAS score 2.6 ± 1.1, P < 0.001).Between baseline and weeks 2, 8, and 12 (end-point) a significant improvement in all 5 dimensions of EQ-5D (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) was observed (P < 0.001). LIMITATIONS: As it is an open-label study, a prospective randomized placebo-controlled study should be designed to confirm the effectiveness of capsaicin 8% patch in patients with lumbosacral pain. CONCLUSIONS: KEY WORDS:
|
Authors | Panagiotis Zis, Nikolitsa Bernali, Erifili Argira, Ioanna Siafaka, Athina Vadalouka |
Journal | Pain physician
(Pain Physician)
2016 Sep-Oct
Vol. 19
Issue 7
Pg. E1049-53
ISSN: 2150-1149 [Electronic] United States |
PMID | 27676676
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Sensory System Agents
- Capsaicin
|
Topics |
- Aged
- Capsaicin
(therapeutic use)
- Female
- Humans
- Low Back Pain
(drug therapy)
- Male
- Middle Aged
- Prospective Studies
- Quality of Life
- Sensory System Agents
(therapeutic use)
- Transdermal Patch
|